Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182808-100μg
|
100μg |
10
|
$69.90
|
|
|
Ab182808-1mg
|
1mg |
4
|
$349.90
|
|
|
Ab182808-5mg
|
5mg |
1
|
$899.90
|
|
|
Ab182808-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,439.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Cendakimab (anti-IL-13) - Primary antibody, specific to IL13, Human IgG1, INHIBITOR of Interleukin-13 inhibitor |
|---|---|
| Synonyms | Allergic rhinitis antibody | ALRH antibody | BHR 1 antibody | BHR1 antibody | Bronchial hyperresponsiveness 1 (bronchial asthma) antibody | IL 13 antibody | IL-13 antibody | Il13 antibody | IL13_HUMAN antibody | Interleukin 13 antibody | interleukin13 ant |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | IL13 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Interleukin-13 inhibitor |
| Product Description |
Cendakimab (anti-IL-13) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab (anti-IL-13) has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab (anti-IL-13) recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab (anti-IL-13) has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.9 kDa (Light Chain) & 50.6 kDa (Heavy Chain), under reducing conditions; 202.3 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2151032-62-9 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Cendakimab (anti-IL-13) (Ab182808) - ELISA
Immobilized IL-13-his at 2.0 μg/mL can bind Cendakimab (anti-IL-13) (Ab182808) with the EC50 of 2.081 ng/mL.
Cendakimab (anti-IL-13) (Ab182808) - SEC
The purity of Cendakimab (anti-IL-13) (Ab182808) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 21, 2024 | Ab182808 | |
| Certificate of Analysis | Jun 21, 2024 | Ab182808 | |
| Certificate of Analysis | Jun 21, 2024 | Ab182808 |
Starting at $109.90
Starting at $109.90
Starting at $69.90
Starting at $49.90
Starting at $59.90
Starting at $109.90
Starting at $109.90
Starting at $109.90
Starting at $109.90